Hematology TimesICER assesses value of CAR T-cell therapiesMarch 27, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesFDA releases updates on BIA-ALCLMarch 22, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesDrug receives orphan designation for CTCLMarch 21, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesLymphoma, breast cancer survivors have greater risk of CHFMarch 13, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesStudy confirms higher risk of infection with CB transplantMarch 1, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersTransplantationHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCompany withdraws application for idelalisibMarch 1, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesAntibody has ‘very promising activity’ in rel/ref CTCLFebruary 15, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesDrug appears safe and active in PTCL, CTCLFebruary 13, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesFDG PET can’t replace BM biopsy, study suggestsFebruary 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesInhibitor provides clinical improvement in MFFebruary 12, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesDrug may be option for B- and T-cell lymphomasFebruary 9, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesAssay identifies actionable mutations in lymphoid malignanciesFebruary 9, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFavorable results with chidamide in rel/ref NKTCLFebruary 8, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesCombo is preferentially active in T-cell lymphomasFebruary 7, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesDuvelisib combos show promise for PTCL, CTCLFebruary 7, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
